Asset Details
Do you wish to reserve the book?
The 15‐Year Survival Advantage: Immune Resilience as a Salutogenic Force in Healthy Aging
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The 15‐Year Survival Advantage: Immune Resilience as a Salutogenic Force in Healthy Aging
Do you wish to request the book?
The 15‐Year Survival Advantage: Immune Resilience as a Salutogenic Force in Healthy Aging
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The 15‐Year Survival Advantage: Immune Resilience as a Salutogenic Force in Healthy Aging
2025
Overview
Human aging presents an evolutionary paradox: while aging rates remain constant, healthspan and lifespan vary widely. We address this conundrum via salutogenesis—the active production of health—through immune resilience (IR), the capacity to resist disease despite aging and inflammation. Analyzing ~17,500 individuals across lifespan stages and inflammatory challenges, we identified a core salutogenic mechanism: IR centered on TCF7, a conserved transcription factor maintaining T‐cell stemness and regenerative potential. IR integrates innate and adaptive immunity to counter three aging and mortality drivers: chronic inflammation (inflammaging), immune aging, and cellular senescence. By mitigating these aging mechanisms, IR confers survival advantages: At age 40, individuals with poor IR face a 9.7‐fold higher mortality rate—a risk equivalent to that of 55.5‐year‐olds with optimal IR—resulting in a 15.5‐year gap in survival. Optimal IR preserves youthful immune profiles at any age, enhances vaccine responses, and reduces burdens of cardiovascular disease, Alzheimer's, and serious infections. Two key salutogenic evolutionary themes emerge: first, female‐predominant IR, including TCF7, likely reflects evolutionary pressures favoring reproductive success and caregiving; second, midlife (40–70 years) is a critical window where optimal IR reduces mortality by 69%. After age 70, mortality rates converge between resilient and non‐resilient groups, reflecting biological limits on longevity extension. TNFα‐blockers restore salutogenesis pathways, indicating IR delays aging‐related processes rather than altering aging rates. By reframing aging as a salutogenic‐pathogenic balance, we establish TCF7‐centered IR as central to healthy longevity. Targeted midlife interventions to enhance IR offer actionable strategies to maximize healthspan before biological constraints limit benefits. Human aging shows puzzling diversity: similar aging rates yet vastly different health outcomes. Our study of ~17,500 people revealed a health‐promoting trait (more common in women) linked to strong immune resilience and high expression of TCF7, a key immune gene. This trait enables individuals to fight infections like COVID‐19 more effectively, respond better to vaccines, avoid comorbidities, and live longer. Its decline after age 70 may explain lifespan limits. These findings redefine aging as a tug‐of‐war between health‐promoting (salutogenic) and disease‐driving (pathogenic) processes, opening new treatment paths.
